Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 13 Parkinson's papers of 4,253 | 0.65 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 13545
Sealed predictions
- LPP in dopamine neurons, braak+0.51 (p 0.161) → -0.30 (p 0.436)receipt 13551
Swarm cases
receipt 13551: LPP in dopamine neurons, braak
- power
- full sample +0.02 (p 0.942, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.03 (p 0.922, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.04 (p 0.861, n 18). could be the mix.
- skeptic
- leave-one-out range -0.06 to +0.16, sign flips 6; without severely affected donors +0.02 (p 0.942, n 18). fragile.
- cell type
- strongest in astrocytes: -0.63 (p 0.0047, n 18) vs +0.02 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LPP in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up LPP · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.02 p 0.929 (needs p < 1.7e-4)
Receipts
loading the receipts